Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, discuss their BioBrace technology in an interview with SmartTRAK at OSET 2025 in Las Vegas. 

Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, sat down with SmartTRAK at the Orthopaedic Summit (OSET) 2025 Annual Meeting in Las Vegas (September 18–25, 2025) to discuss BioBrace and how its bioinductive technology sets it apart from the competition.

To find out more about Conmed and BioBrace, click on the following video (16:30 min). A link to download a complete transcript of the interview is also provided below. 

Hey everybody, it's Andy Knapik with SmartTRAK, here at Ortho Summit in Las Vegas, and I'm happy to be here at the ConMed booth, and joined by a good friend of mine, Lisa Donnelly, who's VP of Marketing for US Ortho for ConMed, and then also Jeff Ott, who is a director of R&D. Why don't you just start by talking to us about how you started with the company? I'm just going to let you go with the intro part.

Jeff Ott: Yes, happy to do that. I joined a small company called Biorez about six or seven years ago as a small startup. We were focused on trying to find ways to help with tendon and ligament healing, and we developed a product called the BioBrace, which now is a part of ConMed.

So, when was that acquired? That was about a year…

Lisa Donnelly: August of 2022.

Okay. So a few years now. Wow. It's flown.

JO: Yes, time has flown by. So the BioBrace, which we developed, we designed a product that is a bioinductive scaffold with strength. What we did is we created a product that can both reinforce a tendon or ligament repair, and it also can ...

Want to learn more about the BioBrace technology? Click the button below to download and read the complete transcript of our exclusive interview with Conmed’s Lisa Donnelly, VP of Marketing for US Orthopedics, and Jeff Ott, Director of R&D, conducted by  Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.

Stephania Bell, a licensed physical therapist, ESPN senior writer, and renowned sports injury analyst, brings together her clinical expertise and media experience, exploring how sports injuries in professional athletes intersect with those seen in the general population.

In a recent interview with SmartTRAK, Stephania Bell, a licensed physical therapist, ESPN senior writer and renowned sports injury analyst, brings together her clinical expertise and media experience, exploring how sports injuries in professional athletes intersect with those seen in the general population.

Click on the following video to watch the interview (43:14 min). For more details, interview topics by timecode and a link to download a complete transcript of the interview are provided below.

Interview Topics By Timecode:

02:00 Stephania’s background.

11:15 Work with Arthrex on the education side.

18:50 Where do med device companies fit in with prevention?

21:51 Patient insistance on being treated like the pros.

29:24 Public perception of sports injuries.

The connection between sports injuries in professionals and those in the broader population offers valuable insight into treatment and recovery trends. Click the button below to download and read the complete transcript of our interview with Stephania Bell, ESPN senior writer and renowned sports injury analyst, conducted by  Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.

Incoming ICRS President Dr. Christian Lattermann discusses the future of cartilage repair in an interview with SmartTRAK at the 2025 ICRS Global Congress in Boston. 

In this interview, SmartTRAK speaks with Christian Lattermann, MD, the incoming president of the International Cartilage Regeneration and Joint Preservation Society (ICRS), about the future of joint repair. He shares insights on emerging technologies, highlighting advances in mechanical correction, AI and biologics. Dr. Lattermann explains how AI helps clinicians understand causes of degeneration that were previously overlooked. He emphasizes the excitement surrounding orthobiologics, especially extracellular vesicles, as a novel approach to guiding biological responses. 

To find out more, click on the following video (22:22 min). Interview topics, organized by timecode, and a link to download a complete transcript of the interview are provided below.

Interview Outline by Timecode:

00:22 The three pillars of revolution: AI, biology, and mechanics.

06:36 Orthobiologics and extracellular vesicles: From "voodoo" to validated science.

10:25 Rethinking inflammation: fixing the "leak."

13:53 The collaborative alliance: industry, clinicians and researchers. 

16:46: Finding the niche: comparing the roles of MACI, Agili-C, and other technologies.

21:29: Conclusion: the future of individualized patient care.

Curious about the future of cartilage repair? Click the button below to download and read the complete transcript of our interview with the incoming ICRS president, Dr. Christian Lattermann, conducted by  Andy Knapik, SmartTRAK Sr. Analyst, Soft Tissue & Arthroscopic Technologies.

Raul Nogueira, MD, discusses the latest research and innovation in super-bore catheters for the treatment of AIS and the preliminary results from the MARRS pivotal trial in an interview with SmartTRAK.

In an interview with SmartTRAK, Raul Nogueira, MD, interventional and stroke neurologist at the University of Pittsburgh and chief of cerebrovascular medicine at the UPMC Stroke Institute, discusses the latest research and innovation in super-bore catheters for the treatment of acute ischemic stroke (AIS), including preliminary results from the MARRS pivotal trial that he recently presented at the Society of NeuroInterventional Surgery (SNIS) 2025 Annual Meeting in Nashville, TN.

Dr. Nogueira highlights key results from the MARRS pivotal trial, which is evaluating Perfuze Medical’s Millipede super-bore 088 catheter, how the results compare to other super-bore pivotal trials and what factors contributed to MARRS’ high first-pass effect rate. 

Listen to the interview below (43:20 min) to learn more, including how Millipede performed in different parts of the brain and the status of research and innovation that is helping to drive growth in the US Market for Mechanical Thrombectomy. A link to download a full transcript of the interview is also provided below.

Interview by Timecode

00:06 Introduction, background about stroke thrombectomy and the evolution of technology and research in mechanical thrombectomy devices.

10:27 Discussion about the MARRS pivotal trial vs other trials and what contributed to the the high, first-pass effect rate.

18:44 Different studies use different definitions of first-pass effect and good reperfusion. Where does the MARRS study definition fit and compare to how other studies define good reperfusion?

21:47 Discussion about safety data for super-bore catheters vs the Millipede catheter, device designs and comparison to other types of thrombectomy devices.

•  CURVAFIX
  Curvafix is redefining pelvic fracture fixation with a novel intramedullary (IM) implant system designed specifically for curved bone anatomy. The company’s flagship device, the CurvaFix IM Implant, is the first and only FDA-cleared implant that ... (read more)
  
  

• Endeavor Orthopedics
  Endeavor Orthopaedics is a trauma-focused medical device company pioneering implant systems for complex avulsion fractures. Its flagship product, the Summit Patella Plating System, addresses a critical need in the treatment of ... (read more)

• Meduloc
  Meduloc is an early-stage orthopedic startup advancing intramedullary fixation solutions for small, long-bone fractures. The company’s proprietary system combines ... (read more)

• OrthoXel
  OrthoXel is an orthopedic trauma company developing advanced intramedullary nailing systems designed to optimize healing biomechanics and surgical workflow. Based in Cork, Ireland, the company has commercialized two flagship platforms ... (read more)

• Reselute Medical
  Reselute Medical is a pre-commercial orthopedic startup developing a novel class of intramedullary implants capable of localized antibiotic delivery for the treatment of severe traumatic long bone fractures. The company’s lead product is ... (read more)

Curious about what's next in Orthopedic trauma and the companies that are rethinking the fundamentals of fracture care? Click the button to get the full article by Nick Fitzpatrick, SmartTRAK Associate Market Analyst – Orthopedics.

TOBI President Michael Khadavi, MD, shares his thoughts on the institute's future, key insights from this year’s conference, and exciting new techniques and technologies in the orthobiologics field.  

Dr. Michael Khadavi, a triple-boarded physician in physical medicine and rehab (PM&R), sports medicine, and ultrasound, and the current president of the Orthobiologic Institute (TOBI), discusses the organization's future plans, including expanding its educational programs, research initiatives and strengthening partnerships with industry in an interview with SmartTRAK. Dr. Khadavi also reviews the use of musculoskeletal ultrasound in orthobiologics and highlights the promising results of intraosseous subchondral injections for joint treatments, citing encouraging data from recent studies. Click on the following video (08:22 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is David Shepard with SmartTRAK. It's my pleasure to be joined by the president of TOBI. This is Dr. Michael Khadavi, triple-boarded physician in PM&R, sports and ultrasound. Thank you very much for joining us.

Michael Khadavi, MD: It is an honor.

Thanks a bunch. So, we're just wrapping up with TOBI, fantastic presentations throughout the week. It's been really, really great. What's your take-home message to all the people that couldn't make it? What are the things that you learned from these last two days? What's the summary of what you learned here?

MK: This was a strong conference, if I've ever been to a good conference. My biggest take-homes are ...

Click the button below to download the full transcript of our exclusive interview with TOBI President Michael Khadavi, MD, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

It is with both gratitude and admiration that we announce the retirement of Susan Paquette, our former VP/GM of SmartTRAK Wound Care, after nearly 15 years of dedicated service to SmartTRAK. 

Since joining the company, Susan has been instrumental in building SmartTRAK Wound Care into the industry’s most trusted source of real-time market intelligence. Under her leadership, the Wound Care business has grown from a promising vision into a powerhouse platform providing comprehensive data, news, and analysis on a range of Advanced Wound Care markets. Today, SmartTRAK Wound Care delivers deep coverage across nine distinct areas with broad global reach, relied upon daily by the world’s top wound and orthopedic companies.

Dr. Steve Sampson, founder of The Orthopedic Institute (TOBI) and the Orthohealing Center, discusses the evolution of orthobiologics, highlighting the integration of machine-based therapies like shockwave and a focus on patient safety, with patients traveling overseas for untested biologic treatments. 

In this interview with SmartTRAK, TOBI founder Steve Sampson, DO, discusses the development of orthobiologics, highlighting a key inflection point where technologies like shockwave and light therapy are used to boost the body's natural healing process. Dr. Sampson also mentions patients traveling abroad for treatments. He warns about the lack of regulatory oversight, potential complications and offers solutions through the Orthohealing Alliance.

Click on the following video (11:10 min) to learn more. A link to download a complete transcript of the interview is provided below.

SmartTRAK: My name is David Shepard. I'm with SmartTRAK, and I'm here at the 16th annual TOBI meeting. and it's my pleasure to be joined by Dr. Steve Sampson. Thanks so much for taking the time. I really appreciate it.

Steve Sampson, DO: Thanks for having me. Looking forward to chatting.

Absolutely. So, the agenda of this year's conference is... It's got a wide range of topics. What do you think is reflected in this year's agenda that really typifies the technologies that are happening out there in the field today?

SS: It's probably the most exciting time in my 20-year career that I feel like we're at this inflection point with new technologies, including machine-based therapies. So, the concept is the human body is remarkable, and we're made of 37 trillion cells, and we have our own drug store, our own ability to self-repair. Our role as physicians is to try to facilitate that. So, machine-based treatments are a big point of this conference where there's a session on shockwave therapy, photo-biomodulation light therapy, hyperbaric oxygen. They're all different machine-based treatments that are trying to boost our body's healing capacity. Then I also have a new session of mesenchymal stem cells or MSCs overseas.

SS: A lot of times, in clinic, we find patients are going to Mexico, Panama, Thailand, and some of them have unlimited resources, but they may not be getting the best level of care and bigger isn't always better.

Right.

SS: So, understanding what are some of the regulatory challenges here in the United States, why are patients going overseas ,,,

Click the button to get the full transcript of our exclusive interview with TOBI founder Steve Sampson, DO, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.